Research programme: inflamation therapeutics - Saverna Therapeutics
Latest Information Update: 08 Sep 2021
At a glance
- Originator Saverna Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action MicroRNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Inflammation
Most Recent Events
- 24 Aug 2021 Inflamation therapeutics - Saverna Therapeutics is available for licensing as of 24 Aug 2021. http://www.saverna.com/investors
- 24 Aug 2021 Early research in Inflammation in Switzerland (PO) before August 2021 (Saverna Therapeutics pipeline, August 2021)